Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
Rhea-AI Summary
Atossa Therapeutics (Nasdaq: ATOS) announced four abstracts featuring (Z)-endoxifen research were accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS), Dec 9-12, 2025 in San Antonio, TX. The company will present four posters on Dec 11-12 covering DCIS management, a low-dose I-SPY2 endocrine pilot, ESR1 mutant activity, and a Phase 2 neoadjuvant EVANGELINE trial.
Presentations include scheduled poster sessions on Dec 11 (12:30pm–2:00pm CT) and Dec 12 (7:00am–8:30am CT and 12:30pm–2:00pm CT).
Positive
- None.
Negative
- None.
Insights
Four SABCS poster acceptances increase visibility for (Z)-endoxifen but provide no new clinical outcomes yet.
Atossa Therapeutics secured four poster presentations at the San Antonio Breast Cancer Symposium on
The business mechanism is straightforward: scientific presentations raise awareness among clinicians and researchers and can accelerate external scrutiny and collaboration. These listings do not report efficacy or safety results in this notice, so the clinical and commercial implications remain undefined.
Key dependencies and risks include the actual data content and statistical strength presented at the sessions, regulatory interpretation of any positive endpoints, and how the Phase 2 EVANGELINE outcomes compare on prespecified non-inferiority margins. Watch the poster sessions on
Studies highlight findings in the use of (Z)-endoxifen to advance breast cancer treatment and prevention
"We continue to add to our body of clinical evidence. At SABCS 2025, we look forward to four poster presentations highlighting findings from studies evaluating the use of (Z)-endoxifen to advance breast cancer treatment and prevention," said Dr. Steven Quay, Atossa Therapeutics President and Chief Executive Officer.
|
Poster Presentation Details: |
|
|
Title: |
Initial results from RECAST DCIS: Multicenter platform trial testing active |
|
Date/Time: |
Thursday, December 11, 2025, 12:30pm - 2:00pm CT |
|
|
|
|
Title: |
Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot |
|
Date/Time: |
Thursday, December 11, 2025, 12:30pm - 2:00pm CT |
|
|
|
|
Title: |
(Z)-Endoxifen Maintains ERα Antagonist Function Against ESR1 Mutants via |
|
Date/Time: |
Friday, December 12, 2025, 7:00am - 8:30am CT |
|
|
|
|
Title: |
A Randomized Phase 2 Non-Inferiority Trial of (Z)-Endoxifen + Goserelin vs Exemestane + Goserelin as Neoadjuvant Treatment for |
|
Date/Time: |
Friday, December 12, 2025, 12:30pm - 2:00pm CT |
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative therapies for significant unmet needs in breast cancer. Atossa's strategy emphasizes disciplined capital allocation, focusing resources on programs and data packages that can enable future regulatory submissions and potential commercialization. For more information, visit www.atossatherapeutics.com and refer to Atossa's filings with the
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding Atossa's commercial readiness, financing strategy, operational plans, and the development and potential commercialization of (Z)-endoxifen. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including market conditions, regulatory outcomes, clinical results, manufacturing and supply, intellectual-property challenges, and the Company's ability to secure sufficient funding on acceptable terms. For a discussion of risks and uncertainties, please refer to Atossa's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-acceptance-of-four-abstracts-highlighting-z-endoxifen-research-for-presentation-at-the-2025-san-antonio-breast-cancer-symposium-302606891.html
SOURCE Atossa Therapeutics Inc
FAQ
What is Atossa (ATOS) presenting at SABCS 2025 and when?
Which (Z)-endoxifen studies will ATOS present at the Dec 11, 2025 poster session?
What are the topics of ATOS's Dec 12, 2025 SABCS presentations?
Does the SABCS schedule for ATOS include clinical trial data for (Z)-endoxifen?
How can investors follow ATOS presentations at SABCS 2025?
What is the significance of ATOS presenting four abstracts on (Z)-endoxifen at SABCS 2025?
